Form 8-K Moderna, Inc. For: Aug 15
- Dow Futures Tick Higher After Indices Extend Rout
- Oil Creeps Higher as Markets Weigh Hurricane-led Supply Disruptions
- Wall Street ends lower, Dow confirms bear market
- S&P 500 Will See 3000-3400 Later This Year, Morgan Stanley's Wilson Warns Again
- Add Equity Exposure As Double Bottom Attempt is Underway - Canaccord Genuity
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
|(Address of principal executive offices)||(Zip code)|
Registrant’s telephone number, including area code:
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
on which registered
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|Item 5.02|| |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b), (c) and (e) On August 17, 2022, Moderna, Inc. (the “Company”) announced that James Mock has been appointed to serve as the Company’s Chief Financial Officer (“CFO”), beginning September 6, 2022. Following the appointment of Mr. Mock, David Meline will retire as the Company’s CFO effective the same date, but will remain as a consultant to the Company to assist with the transition.
Prior to joining the Company, Mr. Mock, 45, served as Senior Vice President and CFO of PerkinElmer, Inc., a life sciences, diagnostics, and analytical solutions company, since May 2018. In his role at PerkinElmer, he had overall leadership responsibility for the strategy and operations of all Company finance functions. During that time, he was instrumental in transforming PerkinElmer into an organization with a strengthened financial profile for growth and profitability. Before that, Mr. Mock served for nearly 20 years in a wide range of financial oversight capacities within General Electric Company (“GE”), both in the United States and overseas. Mr. Mock’s most recent role at GE was Vice President, Corporate Audit Staff, a position in which he served from October 2015 to April 2018.
In connection with his employment with the Company as CFO, and pursuant to the terms of his offer letter, dated August 15, 2022 (the “Offer Letter”), Mr. Mock will receive an initial annual base salary of $750,000. Mr. Mock will also be eligible for an annual cash bonus (commencing with a pro-rated bonus for 2022) with an annual incentive target of 90% of his annual base salary, based upon achievement of certain individual performance goals and/or company performance goals established by the Company. Achievement of the goals will be determined in the sole discretion of the Compensation and Talent Committee of the Board of Directors (the “Compensation Committee”). Mr. Mock will also be eligible to receive a one-time signing bonus of $1,000,000 and a new hire equity award equivalent to a total value of $6,000,000 (the “Equity Grant”), to be granted in accordance with the Company’s Equity Award Grant Policy, which is described on page 49 of the Company’s Proxy Statement for the 2022 Annual Meeting of Stockholders (the “Proxy Statement”). The Equity Grant is subject to a four-year vesting period. For the Equity Grant, Mr. Mock will have the ability to select whether to accept the grant: (1) in the form of a non-qualified stock option, (2) 75% in value in the form of a non-qualified stock option and 25% in value in the form of restricted stock units (“RSUs”), or (3) 50% in value in the form of a non-qualified stock option and 50% in value in the form of RSUs. In addition, subject to the Compensation Committee’s approval, Mr. Mock will be eligible to participate in the Company’s annual equity award program in future years. The target value for this annual equity award will be $3,000,000 to $4,000,000, subject to adjustment by the Compensation Committee.
Mr. Mock will be eligible for all compensation and benefit plans available to the Company’s executive officers, as described in the Proxy Statement. Mr. Mock will participate in the Company’s Amended and Restated Executive Severance Plan and has entered into an indemnification agreement with the Company, consistent with the form of the existing indemnification agreement entered into between the Company and its executive officers. Mr. Mock has also entered into an employee confidentiality, assignment, nonsolicitation and noncompetition agreement.
The above summary is qualified in its entirety by reference to the Offer Letter, a copy of which will be filed with the Company’s future periodic filings.
Pursuant to the terms of the Updated Executive Retirement and Strategic Consulting Agreement between the Company and the Company’s current CFO, David Meline (the “Retirement and Consulting Agreement”), Mr. Meline will voluntarily retire from the Company on September 6, 2022 (the “Retirement Date”), effective upon Mr. Mock’s commencement of service as CFO. Until the Retirement Date, Mr. Meline will continue to serve as CFO pursuant to the terms of the Retirement and Consulting Agreement, a copy of which was filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K/A filed on June 1, 2022.
|Item 7.01|| |
Regulation FD Disclosure.
On August 17, 2022, the Company issued a press release announcing the appointment of Mr. Mock as CFO. A copy of this press release is furnished as Exhibit 99.1 to this Report on Form 8-K.
The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
|Item 9.01|| |
Financial Statements and Exhibits.
|99.1||Press release by Moderna, Inc. dated August 17, 2022|
|104||Cover Page Interactive Data File (embedded within the Inline XBRL document)|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Date: August 17, 2022||MODERNA, INC.|
|Shannon Thyme Klinger|
|Chief Legal Officer|
JAMES MOCK JOINS MODERNA AS CHIEF FINANCIAL OFFICER
CAMBRIDGE, MA / ACCESSWIRE / August 17, 2022 / Moderna, Inc., (NASDAQ: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that James Mock has been appointed as Modernas Chief Financial Officer, beginning September 6, 2022. He will serve on Modernas Executive Committee and report to Chief Executive Officer Stéphane Bancel. Following the appointment of Mr. Mock, David Meline will retire as the Companys CFO effective the same date but will remain as a consultant to the Company to assist with the transition.
I am thrilled to welcome Jamey to Modernas Executive Committee as our Chief Financial Officer. Moderna is at an exciting stage with a growing mRNA platform, including four Phase 3 trials occurring this year and upcoming proof-of-concept data in rare diseases and immuno-oncology, significant commercial momentum and a strong financial position, said Stéphane Bancel, Chief Executive Officer of Moderna. Jameys experience in scaling global businesses will ensure we continue to be well positioned for the future. I look forward to working with Jamey and welcoming him to Moderna. At the same time, I remain very grateful for the many contributions and steady leadership that David has provided Moderna and wish him the best in his well-deserved retirement.
Prior to joining the Company, Mr. Mock served as Senior Vice President and CFO of PerkinElmer, Inc., a life sciences, diagnostics and analytical solutions company, since May 2018. In his role at PerkinElmer, he had overall leadership responsibility for the strategy and operations of all Company finance functions. During that time, he was instrumental in transforming PerkinElmer into an organization with a strengthened financial profile for growth and profitability. Before that, Mr. Mock served for nearly 20 years in a wide range of financial oversight capacities within General Electric Company, both in the United States and overseas.
I am thrilled to join the Moderna team as they continue their inspirational and ground-breaking work in bringing the promise of mRNA to the world, said Mr. Mock. This is a company with an exceptionally bright future and it is a privilege to be part of it.
Mr. Mock holds a Bachelor of Arts in economics from St. Lawrence University.
In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators. Most recently, Modernas capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic.
Modernas mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding the Companys appointment of Mr. Mock as Chief Financial Officer and the scaling of Modernas business. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Modernas control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include those other risks and uncertainties described under the heading Risk Factors in Modernas Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022, each filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SECs website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Modernas current expectations and speak only as of the date hereof.
Vice President, Corporate Communications
Senior Vice President & Head of Investor Relations
SOURCE: Moderna, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U.S. FDA clears additional lots of Moderna's Covid booster amid shortage
- Grab targets Group Adjusted EBITDA breakeven by H2 2024 as it accelerates path to profitability
- Sampo plc’s share buybacks 26/09/2022
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!